Regulators catching up on global enforcement
This article was originally published in Scrip
Executive Summary
In the globalisation race, regulation often comes a poor second to commercial enterprise. Certainly where drug quality and safety are concerned, the rapid growth in outsourcing of manufacturing and clinical trials to countries like India and China has left regulators in the US and Europe struggling to ensure that GMP and GCP standards are being met.